Filing summary
Entity check: The supplied filing is Miragen Therapeutics, Inc.’s Form 10-Q for the quarter ended June 30, 2020 (ticker MGEN), not a filing identified as Viridian Therapeutics, Inc. Confirm the issuer before relying on this summary.
Business context and reporting period
Miragen was a clinical-stage biotechnology company developing RNA-targeted therapies. Its candidates included cobomarsen for certain cancers, remlarsen for fibrosis, and MRG-110 for heart failure, wound healing, and ischemic disease; MRG-229 was in preclinical development. The company had no approved products and no product-sales revenue. Financial results cover the three and six months ended June 30, 2020, compared with the same 2019 periods.
Key financial metrics
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Total revenue | $0.168m | $2.514m | $0.996m | $2.886m |
| Research and development expense | $3.836m | $8.599m | $9.939m | $17.350m |
| General and administrative expense | $2.706m | $2.857m | $5.429m | $6.214m |
| Net loss | $6.435m | $8.896m | $14.479m | $20.525m |
| Basic and diluted loss per share | $0.12 | $0.29 | $0.29 | $0.66 |
| Operating cash used | Not separately stated | Not separately stated | $15.248m | $18.983m |
At June 30, 2020, cash and cash equivalents were $30.582m, with no short-term investments; total current assets were $32.521m and current liabilities $6.723m. Total liabilities were $12.314m and stockholders’ equity $21.171m. Notes payable had $8.059m principal outstanding, while the balance-sheet carrying value was $8.797m. Management estimated cash would fund operations into the third quarter of 2021. No operating margin was reported; the company remained loss-making.
Material changes versus prior periods
- Q2 revenue fell $2.346m year over year, primarily because reimbursable research and development activity under the Servier collaboration declined. Servier’s termination became effective in February 2020; six-month 2020 collaboration revenue was $0.681m versus $2.846m in 2019.
- Q2 R&D expense decreased $4.763m and six-month R&D expense decreased $7.411m, principally reflecting lower cobomarsen SOLAR trial and related manufacturing activity, personnel costs, and other expenses.
- Net loss narrowed by $2.461m in Q2 and $6.046m for the first six months, as lower operating expenses more than offset reduced revenue.
- Cash increased from $24.846m at December 31, 2019 to $30.582m at June 30, 2020. First-half financing provided $18.983m, including a February public offering that generated approximately $13.9m net and approximately $1.7m from a PPP loan.
- Common shares issued and outstanding rose to 53.077m from 34.862m at year-end 2019. The February offering also included warrants for 7.5m shares at $1.10 per share.
Outlook, commentary, risks and unusual items
- Management expected available cash to fund operations into Q3 2021, but stated that substantial additional capital would be required. Financing availability, clinical progress, and market conditions could shorten the runway; failure to raise funds could force program delays, reductions, or discontinuation.
- COVID-19 affected some SOLAR trial sites. As of July 17, 2020, 34 of 37 CTCL patients were being followed for response and 32 continued uninterrupted treatment. The company no longer expected SOLAR topline data in Q3 2020 and could not predict when results would be available.
- Management planned to meet with the FDA before the end of 2020 to discuss cobomarsen’s development path in ATLL. For MRG-229, a non-human-primate toxicology study had begun, with additional preclinical safety and efficacy data expected before year-end 2020.
- A restructuring begun in August 2019 targeted about 44 positions, roughly half the then-workforce, to focus resources on cobomarsen and miR-29 mimics. Cumulative restructuring expense was approximately $2.3m through June 30, 2020; about $0.1m of further expense was expected in the remainder of 2020.
- The $1.7m PPP loan bears 1% interest and may be forgiven subject to program conditions. The company gave no assurance of forgiveness and disclosed potential repayment, penalty, and reputational risks related to eligibility and its application.
- Nasdaq’s minimum-bid-price requirement was regained on June 30, 2020 after a prior deficiency notice; continued listing remained a risk. The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls.
Important facts for investors to verify
- Confirm that Miragen Therapeutics, Inc.—rather than Viridian Therapeutics, Inc.—is the intended issuer and reporting period.
- Assess the cash runway against operating cash use, debt service, and the company’s need for additional financing.
- Review SOLAR trial data timing and the FDA feedback and next steps for cobomarsen, including in ATLL.
- Track MRG-229 toxicology results and whether stated preclinical milestones were achieved.
- Verify PPP loan forgiveness status and review the potential dilution from equity sales, options, and the 7.5m outstanding offering warrants.